spacer
home > pmps > winter 2018 > patience with patients
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Patience with Patients

What is patient adherence?

As defined by the WHO, patient adherence is the extent to which a personís behaviour Ė for example, taking medication, following a diet or executing lifestyle changes Ė corresponds with the agreed recommendations from a healthcare provider. A low level of adherence means that the likelihood of patients taking their prescribed medication correctly is small, which can be very dangerous, in some cases.

Would you say that this is a growing or lessening concern for the pharmaceutical industry and why?

Patient adherence is currently one of the biggest challenges that the pharma industry is facing and remains a growing concern. Not only do low patient adherence levels affect healthcare efficacy, it is also extremely costly to the industry. Research shows that patients not taking their medication in line with recommendations costs the NHS £500 million per year, which, in context, is equivalent to 30,000 kidney transplants or an extra 21,000 qualified nurses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rupert Taylor joined Essentra in 2014 as Global Category Manager Household for food and drink. He is now Global Category Manager for healthcare and personal care. Rupertís role is to identify customer and consumer needs in the market place and deliver those solutions through the companyís portfolio of packaging, components, special technologies, security, and authentication. Prior to joining Essentra, he worked as Marketing and Innovation Director for Puratos, Brazil. Rupertís experience spans over 20 years in delivering results in both B2B and B2C environments on a global basis.
spacer
Rupert Taylor
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biosimilar Drug Development the analytical strategy is keyfactor for your success

Heilbronn/Dortmund March 2019: The generation of analytical data for the comparison between a biosimilar and the originator product is the initial assumption in the development of biosimilars. Achieving Biosimilarity can be a controversial and complex topic when deciding the right time point and range of analytics.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement